Calprotectin Levels in Necrotizing Enterocolitis

Completed

• Conditions: Necrotising Enterocolitis Neonatal

• Registration Number: NCT06693154
• Lead Sponsor: Ankara Yildirim Beyazıt University

Brief Summary

Necrotizing enterocolitis (NEC) is a serious condition that can affect premature babies, leading to complications like intestinal damage and infection. In our study, we measured specific markers (called calprotectin) in blood and stool to understand how severe NEC is and predict outcomes. We found that these markers were higher in babies with more severe NEC (stage 3), especially in those who needed surgery or sadly did not survive. This information can help doctors detect NEC earlier, understand its severity, and make better decisions for treating affected babies.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-01
• Primary Completion: 2024-01-01
• Study Completion: 2024-06-01
• Status Verified: 2024-11
• Study First Submitted: 2024-11-15
• Study First Submitted QC: 2024-11-15
• Last Update Submitted: 2024-11-15
• Study First Posted: 2024-11-18
• Last Update Posted: 2024-11-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 59

Inclusion Criteria

before 32 weeks of gestation with a birth weight of ≤1500 grams

Exclusion Criteria

Infants whose families did not provide consent and those with congenital anomalies were excluded.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The predictive value of serum and fecal calprotectin levels in necrotising enterocolitis (NEC)	2 years	The predictive value of serum and fecal calprotectin levels in assessing NEC severity (stage 2 and stage 3), intestinal perforation, the need for surgery, and mortality.

Trial Locations

Locations (1)

Ankara Bilkent City Hospital; 🇹🇷 Ankara, Turkey